Physician profile
Amber E Niewald
NPI 1881892487
$594.67
in general payments reported to CMS, 2019-2025
12 companies · $28.54 in 2025
The $28.54 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $62.98 · 2021: $88.36 · 2022: $65.14 · 2023: $142 · 2024: $97.94 · 2025: $28.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $268.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $112.77 | 2021-2023 | |
| Pfizer INC. | $102.81 | 2019-2024 | |
| Lilly USA, LLC | $81.08 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $64.66 | 2019-2020 | |
| Novo Nordisk INC | $61.12 | 2022-2023 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $53.32 | 2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.27 | 2019-2020 | |
| Hologic Sales and Service, LLC | $20.60 | 2023 | Third Wave, Thinprep 2000 Processor, Aptima |
| Pharmacyclics LLC, An Abbvie Company | $14.80 | 2023 | |
| Novartis Pharmaceuticals Corporation | $14.68 | 2025 | |
| Allergan, INC. | $12.19 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Niewald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.